Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Zhongzhi Pharmaceutical Holdings Limited ( (HK:3737) ) just unveiled an announcement.
Zhongzhi Pharmaceutical Holdings Limited has scheduled a board meeting in Hong Kong on 26 March 2026 to review and approve the audited annual results for the year ended 31 December 2025. The board will also consider whether to recommend a final dividend for 2025, a decision that could affect shareholder returns and signal management’s confidence in the company’s recent financial performance.
The announcement, signed by chairman and executive director Lai Zhi Tian, confirms the current composition of the eight-member board, including executive, non-executive and independent non-executive directors. The planned review of results and potential dividend underscores a routine yet important governance milestone that may influence investor sentiment toward the company’s financial health and capital allocation priorities.
The most recent analyst rating on (HK:3737) stock is a Buy with a HK$0.78 price target. To see the full list of analyst forecasts on Zhongzhi Pharmaceutical Holdings Limited stock, see the HK:3737 Stock Forecast page.
More about Zhongzhi Pharmaceutical Holdings Limited
Zhongzhi Pharmaceutical Holdings Limited is a Hong Kong-listed company in the pharmaceutical industry, incorporated in the Cayman Islands and traded under stock code 3737. The group operates through a board comprising executive, non-executive and independent non-executive directors, reflecting a conventional governance structure for a regional pharmaceutical player.
Average Trading Volume: 671,897
Technical Sentiment Signal: Buy
Current Market Cap: HK$711.5M
For an in-depth examination of 3737 stock, go to TipRanks’ Overview page.